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ABSTRACT 
THE CHANGES OF FRUCTOSE-2,6-BISPHOSPHATE LEVEL IN 
TRANSGENIC MICE CAUSING CARDIOMYOPATHY 
Jianxun Wang 
June 19, 2007 
Heart failure is recognized as a major cause of death among 
diabetics. In type I and II diabetes, glucose uptake, glycolysis and pyruvate 
oxidation are impaired, and fatty acid utilization increases These alterations 
in metabolism contribute toward cardiac contractile function. There is a gap 
in our understanding on how alterations in glycolytic metabolite 
fructose-2,6-bisphosphate (F-2,6-P2) affects cardiac dysfunction. Two 
cardiac-specific overexpression of PFK-2 (phosphofructose kinase-2) 
transgenic models were used to investigate the role of altered metabolism by 
F-2,6-P2 in provoking cardiomyopathy. One model is with the PFK-2 kinase 
active and phosphatase inactive enzyme called MK and another model is the 
PFK-2 kinase inactive and phosphatase active enzyme called Mb. The effect 
of PFf<2 transgenes was evaluated by Langendorff -perfused heart in vitro. 
Cardiomyopathy was assessed by measurement of heart to body weight 
ratio and cardiac histology. The study shows that changes in F-2,6-P2 level 
could mduce cardiac hypertrophy and fib:rosis and cause cardiac dysfunction, 
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INTRODUCTION 
Significance and Background 
Diabetes mellitus is the worlds fastest growing disease. Almost 
20.8 million children and adults in the United States have diabetes. Type 1 
diabetes can not produce insulin due to pancreatic ~-cell dysfunction and 
type 2 diabetes can not properly use insulin due to insulin resistance and 
pancreatic ~-cell dysfunction. An association between diabetes and cardiac 
disease was first recognized in the late 1800s. More recently, the 
Framingham Heart Study 1. 2 provided conclusive evidence of the role of 
diabetes in heart failure: in a prospective study of 5,000 individuals, the risk 
of heart failure was increased in diabetic men and women by two- and 
five-fold respectively and heart failure is now recognized as a major cause of 
death among diabetics 3 Diabetic patients usually exhibit diabetic 
cardiomyopathy, leading to congestive heart failure. Diabetic 
cardiomyopathy is characterized by impaired cardiac contractility and poor 
myocardial performance without vascular or valvular disease4 Several 
metabolic complications which are involved in diabetic cardiomyopathy are 
common to both types1 and 2 diabetes. For example, hyperglycemia and 
elevated free fatty acids (FFA) are present in type 1 and 2 diabetes. Although 
the time course of developing ventricular dysfunction may be different, the 
cardiac consequences of both types of diabetes are similar. However, the 
mechanisms by which diabetic cardiomyopathy develops is still unclear .. A 
better understanding of cardiomyopathy development during diabetes can 
provide information for the treatment of cardiomyopathy. 
Under normal conditions, fatty acids provide 70% and glucose and 
lactate provide 30% energy for heart5. 6 7. (see figure 1) In pathophysiologic 
conditions, such as cardiomyopathy, the heart can rapidly switch its 
substrates between glucose and fatty acids to ensure continuous ATP 
generation for maintaining heart function 8. 9. 10. 11 12. 13. 14. However, this 
transition has also been associated with deleterious consequences. In type I 
and type II diabetes mellitus, glucose uptake, glycolysis and pyruvate 
oxidation are impaired, and fatty acid utilization increases. This alteration in 
metabolism contributes toward cardiac contractile dysfunction 15, other 
factors contributing to diabetic cardiomyopathy, such as changes of Ca2+ 
homeostasis, decreased cardiac efficiency, liptoxicity and myocardial 
mitochondrial damage, have also been linked to alterations in myocardial 
metabolism. These changes in cardiac metabolism are learly events and 
precede the development of cardiomyopath/ 6 . Furthermore, normalizing 
cardiac metabolism in diabetic animals can reverse ttle development of 
cardiomyopathi 7 18.19 . Therefore, a proper balance of cardiac metabolism 
is a key factor to maintaining a healthy heart. Disruption of the balance of 
myocardial metabolism by high glucose and/or by hyperlipidemia could result 
in cardiomyopathy. 
There is a gap in our understanding of how alterations in the 
glycolytic metabolite, fructose-2,6··biphosphate (F-2,6-P2), affects cardiac 
function. F-2,6-P2 is a key regulator of phosphofructose kinase-1 (PFK-1), 
2 
one of the rate-limiting steps of glycolysis ( see figure 1). In hepatic cells, 
increased F-2,6-P2 can also modify expression of genes involved in 
carbohydrate mE~tabolism, increasing expression of !~Iucokinase and 
inhibiting expression of glucose-6-phosphatase, meanwhile the expression 
of two key lipogenic enzymes, acetyl-eoA carboxylase and fatty acid 
synthetase, is reduced. 47 Therefore, changes in F-2,6-P2 levels in the heart 
may disturb thE~ balance of cardiac metabolism. 
Glucose upta.ce and utilization 
In the heart, cardiac glucose uptake is driven by a glucose gradient 
and is dependent on the density of sarcolemmal glucose transporters such as 
Glut1 and Glut4. Under basal conditions without insulin stimulation, Glut4 is 
located in an intracellular pool and Glut1 is primarily located on the sarcolemma 
membrane, therefore, Glut1 transporter regulates basal glucose uptake. Upon 
activation by insulin, however, Glut4 will translocate to the cell membrane to 
transport glucose2o 21.22, as a major contributor for glucose uptake. After 
gluCOSE! enters the cardiornyoctye glycolysis occurs. Glycolysis is controlled by 
a network of enzymes including hexokinase, PFK-1 and PFK-2. After glycolysis, 
pyruvate can enter mitochondria for oxidation. Glycolysis is far more 
complicated than just breaking down glucose. ATP derived from glycolysis 
seems to have a preferential role in maintaining normal conductance for 
calcium, potassium and sodium ions in the cell membrane:23· 24. 25. In isolated 
perfused hearts., increased utilization of glucose can decrease ischemic 
damage while decreased utilization of glucose tends to sensitize the heart to 
ischemia 50. 
The glycolytic rate is lower in diabetics. A low rate of glycolysis will 
impact heart function, even leading to cardiomyopathy15. F-2,6-P2 is a key 
regulator of PFK-1, one of the rate limiting steps of glycolysis. Decreased 
F-2,6-P2 mimics the situation in diabetes and will reduce the glycolytic rate. In 
diabetic states, hepatic F-2,6-P2 levels are low due to insulin deficiency, or 
relatively low due to insulin resistance49 . If this low level of hepatic F-2,6-P2 is 
raised, however, blood glucose levels could be reduced, and many of the 
metabolic consHquences of type 2 diabetes could be ameliorated 26 27. 
Proposed mechanisms for functional recovery by increased F-2,6-P2 are that 
F-2,6-P2 increases AKT phosphorylation, favors glycolysis and suppresses 
gluconeogenesis through allosteric activation of PFK1 28. Therefore, decreased 
F-2,6-P2, leading to reduction of glycolysis and ATP, will dHcrease ion channel 
activity on the cardiomyocyte membrane and reduce membrane potential. We 
therefore hypothesize that decreased F-2,6-P2 in the Mb transgenic model 
mouse will result in cardiomyopathy. 
Hyperglycemia can provoke glucotoxicity, causing cardiac tissuH 
injury due to excess production of reactive oxygen species (ROS), leading to 
release of cytochrome C and activation of Poly (ADP-ribosH) polymerase-1 
(PARP) 29. PARP, through inhibition of glyceraldehyde phosphate 
dehydrogenase (GAPDH), diverts glucose from glycolytic pathways to other 
pathways, including polyol and hexosamine pathway flux 30. In the polyol 
pathway the cell will be depleted of NADPH and GSH, and oxidative stress will 
increase. In the hexosamine pathway, activities of some transcriptional factors 
such as SP1 will be affectE~d and gene expression profiles will be altered. 
Increased F-2,6-P;: can increase glycolytic rate and decrease intracellular 
glucose levels. In the MK transgenic mouse, this decrease of intracellular 
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glucose could facilitate glucose uptake by the transporter (:;lut1 using the 
energy of the glucose gradient potential mimicking the high !~Iucose level of 
diabetes, exhibitin~J glucotoxicity. We hypothesize that excess F-2,6-P2, through 
multiple pathways such as the polyol and hexosamine pathways, contributes to 
the development of cardiomyopathy. 
Fatty acid uptake and utilization 
Three fatty acid (FA) transport proteins have be'en identified In the 
heart,: C036, FA transport protein (FATP) and FA binding protein plasma 
membrane (F/~BPpm)31. Once the FA enters cardiomyocytes, the FA will be 
esterfied by acyl-CoA synthase (ACS), the fatty acyl··CoA can then be 
transported into mitochondria for oxidation or stored as tri91ycerides (Tg). In 
normal heart, there is a balance between lipogenesis and lipolysis to control 
intracellular T~I level 32. If FA supply is far more than cellular oxidative 
capacity, Tg can accumulate and lipotoxictiy follows. For E~xample, transgenic 
mice overexpressing cardiac ACS, FATP or LPL ( lipoprotein lipase) 
demonstrated that increased FA uptake and utilization of FA and/or lipid 
accumulation correlated well with contractile dysfunction 33 34,35 In human 
diabetic patients, increased FA utilization is associated with augmented 
cardiac oxygE~n consumption and reduced cardiac efficiency. Reduction of 
cardiac efficiency and increased oxygen demand makes Ule heart especially 
vulnerable to damage following increased workloads or ischemia. 15 
Accumulation of FA leads to augmented intracellular FA derivatives, such as 
fatty acyl-CoA, diacylglycerol and ceramide.36 37. 38 ThHse FA metabolites 
activate a serine kinase cascade which phosphorylate~s serine of insulin 
receptor substrate (IRS). Serine phosphorylation of IR~S·-1 reduces tyrosine 
phosphorylation of IRS-'l, resulting in insulin resistanc:e,39 40. 41, 42, 43 
Therefore, decreased F-2,6-P2 will reduce glycolysis and !Jlucose oxidation 
and potentially stimulate cardiomocytes to transport more fatty acids to 
compensate for the deficiency of ATP, leading to accumulation of FA 
metabolites and rE!sulting iln cardiomyopathy (see figure 3), 
Cross talk between fatty acid and glucose utilization 
Healthy hearts derive most of their energy from frE!e fatty acids and 
only a small proportion from circulating glucose, However, diabetic hearts use 
more fat and IE~ss glucose than normal hearts44 , For example, FA oxidation 
accounts for 93% of calculated ATP production in diabetic hearts compared 
with 64% in control hearts, Glycolysis accounts for only 4% of ATP production 
in diabetic hearts relative to 11 % in normal hearts, and glucose oxidation 
accounts for only 3% of ATP production compared with 25% in control 
hearts,45 In contrast to diabetic hearts, there is an increase in cardiac glucose 
usage and a rE~duction in fat consumption after a myocardial infarction, 
Overexpression of LPL in the heart accelerates FA uptake, conversely, tissue 
specific knockout of LPL causes heart to prefer glucose, The presence of 
glucose also can reduce fatty acid metabolism, probably by increaSing 
intracellular level of malonyl-eoA ( see figure 2), ThesE=~ alterations of 
cardiac metabolism are important causative factors in the development of 
cardiomyopathy, as shown in the perfused hearts from leptin receptor deficient 
(db/db) mice and transgenic db/db-hGLUt4 mice which overexpress Glut4, 
Reduced fasting hyperglycemia and improved glucose disposal after an oral 
glucose challenge in db/db-Glut4 mice was observed when compared to db/db 
mice48 while reduced contractile performance in db/db mice was also 
6 
completely normalized in db/db-Glut4 mice.45 
Some studies show that activation of cardiac PPAR-a not only favors 
FA oxidation but also inhibits glucose uptake' and utilization, leading to 
augmented susceptibility to ischemic damage. Knockout of cardiac PPAR-a 
prevents suppression of GLUt4 expression and glucosf~ uptake by elevated 
plasma FA and improves myocardial recovery from ischemia,46 the 
mechanisms that explain how changes of cardiac metabolism are involved in 
diabetic cardiomyopathy are still unclear. We hypothesize that decreased 
F-2,6-P:< will shift the cardiac metabolite from glucose to F'A utilization and 
increased F-2~,6-P2 shift the cardiac metabolite from FA to ~llucose utilization. 
The shift between glucose and fatty acid utilization may cause abnormal 
cardiac function e.g. heart hypertrophy, heart failure and cardiomyopathy. 
7 
FIGURE 1 
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Fig.1. A balance between glucose and fat consumption exists in the healthy 
cardiomyocyte. Glucose is transported into cytosol by glucose transporters 1 
and 4, and provides 30% of the energy for the heart through glycolysis and 
glucose oxidation as shown in the left pathway. Fatty acid is transported into 
cytosol by transporters FAT/CD36 etc. for fatty acid oxidation, and provides 
70% the energy for the heart as shown in the right pathway. 
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FIGURE 2 




t .. cytosol 
G-6-P ~ t & 
Citrate 
Glucose 
Fig.2. Randle cycle. Glucose metabolites interact with fatty acid metabolites 
within mitochondria and cytosol. Fatty acid-CoA in cytosol is transported into 
the mitochondrion by transporters CPT I and CPT II. Acetyl-CoA can be 
produced from fatty acid in mitochondria via j3 -oxidation. The acety-CoA 
derived from fatty acid oxidation inhibits the activity of pyruvate 
dehydrogenase complex (PDC) to reduce glucose oxidation, and also enters 
the TCA cycle for the synthesis of citrate. The citrate can diffuse out of the 
mitochondrion to the cytosol, inhibiting the activity of PFK-1 which will result 
in the accumulation of G6P. The accumulated G6P will inhibit the activity of 
9 
hexokinase (HK), and meanwhile the accumulated fatty acid-CoA in the 
cytosol can also inhibit the activity of HK, with overall reduction of glycolysis 
and glucose oxidation. Acetyl-CoA derived from glucose can form 
acetyl-carnitine which is transported out of the mitochondrion to release the 
glucose-derived acetyl-CoA, favoring synthesis of malonyl-CoA in the cytosol. 
The increase of malony-CoA will directly inhibit the activity of the transporter 
CPT I, leading to reduction of the fatty acid oxidation. 
6) Indicates inhibition. 
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FIGURE 3 
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1 1 -.......... .. .. .. I AKT ~ 
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Heart failure 
Fig.3. The signal pathways induced by the intracellular accumulation of fatty 
acids are involved in the development of heart failure. The pathways can be 
divided into three parts: cardiac dysfunction, apoptosis and insulin resistance. 
Fatty acid acyl-GoA accumulation in the cytosol can increase the expression 
of PPAR a , resulting in an increase of the expression of slow contractile 
protein f:\ - myosin heavy chain, and can activation of K-ATP channel opening, 
leading to a decrease of ca2+ flux. Both the increase of f:\-MHG and 
decrease of ca2+ flux will decrease cardiac contractility and cardiac 
dysfunction follows. Fatty acid acyl-GoA accumulation in the cytosol can 
raise intracellular oxidative stress (ROS) damaging the mitochondria and 
stimulating the synthesis of ceramide, with a resulting increase in caspase 3 
II 
activity and cytochrome C release which result in an increase in apoptosis. 
Insulin resistance also can be induced by the accumulation of fatty acid 
acyl-CoA through decreasing phosphor-AKT signalingl. 
upregulation, ~ indicates downregulation. 
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METHODS AND MATERIALS 
1. Development of transgenic mice 
The bifunctional enzyme 
6-phosphofructo-2-k.inase/fructose-2,6-bisphosphatase (PFK2) controls 
levels of F-2,6-P2 by catalyzing two opposing reactions: F-6-P + ATP ---'t 
F-2,6-P2 + ADP and F-2,6-P2 ~ F-6-P + PII. 1.6 kb Kpnl/Hindlll fragments of 
the kinase mutant PFK2 cDNA or the bisphosphatase mutant PFK2 cDNA 
was produced by polymerase chain reaction. An insertion DNA fragment for 
cardiac specific expression was obtained by cutting a ligated plasmid in 
which the deficient PFK2 cDNA was inserted behind the a-myosin heavy 
chain promoter. The insertion DNA fragments for kinase 
active/bisphosphatase mutant PFK2 or kinase mutantlbisphosphatase active 
were injected into fertilized embryos to produce trans~lenic animals The 
transgenes were designated Mk (for the MHC promoter and the kinase active 
with bisphosphatase deficient PFK2 gene) and Mb (for the MHC promoter 
and the bisphosphatase active with kinase deficient PFK2 gene).Transgenic 
mice were produced on the FVB background and maintained as 
heterozygotes by breeding to FVB mice. All procedures conformed to the 
Guide for the Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH Publication No. 85-23, revised 1996) and 
13 
were approved by the USDA certified institutional animal care committee. 
Male mice aged 90-130 days were used in the following studies. 
2. Analysis of F-2,6-P2 content in transg,enic mice 
The concentration of F-2,6-P2 was measured in the three groups of 
mice: FVB control, Mb and Mk. First, 0.1 g of heart tissue was homogenized 
in 10 volumes (1 ml) of 50 mM sodium hydroxide, then the tissue was 
solubilized by heating at 80 a C for five minutes. The solution was cooled on 
ice, neutralized with 100 III of 1 M ice cold acetic acid in 20 mM Hepes and 
the supernatant containing F-2,6-P2 was collected by centrifugation at 8000g 
for 10 minutes. 0.25 ml of the reaction mixture (100 mM TES, pH 8.0, 6 111M 
MgCI2, 1 mM EOTA , 0.1 mM OTT and 0.22 mM NAOH) was mixed with 20 
ul of the supernatant, then 25 ul of 50 mM NaPPi (Sodium pyrophosphate) 
was added. The changes in absorbance for 10 min at 340nm were recorded 
along with F-2,6-P2 standards. 
3. Cardiac perfusion 
Mice were anesthetized with ketarnine (50 mg/kg, i.p.) and xylazine 
(2.5 mg/kg, i.p.) and given heparin (10 U/g, i.p.). The hearts were 
retrogradely perfused at 2 ml/min with Krebs-Henseleit buffer (KH) consisting 
of 120 mM NaCI, 20 mM NaHC03, 4.6 mM KCI, 1.2 mM KH2P04 , 1.2 mM 
MgCb, 1! .25 mM CaCb 5 mM glucose and 0.25 J..lCilml of [5-3Hjglucose. 
Throughout the perfusion KH buffer was continuously equilibrated with 95% 
0 2/5% CO2 which maintained a pH of 7.4 and temperature was maintained at 
3rC. The hearts were paced throughout the procedure at 6 Hz (6 V, 3 ms). 
For studying the effect of insulin, baseline !~Iycolysis was determined for the 
14 
first 30 min followed by SO min in the presence of 200 /-lU/ml insulin. 
Glycolysis in the presence of palmitate was measured by bringing the 
perfusatH to O.4mM palmitate by addition of 1/20th volume of 8mM palmitate 
bound to 10% BSA in KH buffer. Perfusion pressure was monitored on a 
Gould/Statham p23Db physiological pressure transducer. Contractile force 
was measured with a Grass FT03 force transducer hooked to the apex of the 
heart. Transducers were connected to a ETH 400 bridge amplifier which fed 
into a Powerlab/400 amplifier. Data were analyzed using AD InstrumEmts 
Chart for Windows version 3.3.S. 
4. Measurement of glycolysis and lactate production 
Tritiated water produced from [S-3H] glucose during the perfusion 
was determined by diffusion. A 400-1.11 sample of cardiac effluent and 2S pi of 
0.6 N HCI were added to 1.S-ml tubes that WHre placed inside 20-ml 
scintillation vials containing 2 ml water. Vials were incubated for 72 h at 3rC. 
The inside tube was removed and Ecolite scintillation fluid was added for 
counting. Effluent from each time point was assayed in triplicate. For each 
experimE~nt, background counts were determined by performing the S8lme 
equilibration with perfusion media that had not passed through the heart. 
Diffusion efficiency was also measured in each experiment using tritiated 
water. Lactate concentration was measured in a 6-fold diluted effluent using 
Sigma kit 826-B. 
5. Isolation of adult mouse ventricular myocytes97 • 
Mb, Mk and FVB control mice were anesthetized with ketamine (SO 
15 
mg/kg, i.p.) and xylazine (2.5 mg/kg, i.p.) and given heparin (10 U/g, i.p.). 
Their hearts were rapidly removed and perfused at constant pressure 
(100 cmH20) at 3rC for -3 min with a Ca2+-free bicarbonate-based buffer 
containing (in mM) 120 NaCI, 5.4 KCI, 1.2 MgS04 , 1.2 NaH2P04 , 5.6 glucose, 
20 NaHC03 , 10 2,3-butanedione monoxime (BDM; Sigma), and 5 taurine 
(Sigma), with oxygenation (5% C02/95% O2). Then the perfusate buffer 
was changed to digestion buffer containing Ca2+-free bicarbonate buffer plus 
collagenase (0.5mg/ml) and CaCI2 0.05mM for 7- 10min until the hearts 
became swollen and flaccid. The hearts were removed from cannulation and 
the left ventricles were separated with blunt forceps in 2 ml digestion buffer. 
The minced tissues were gently agitated by repeated pipette aspiration, 
filtered through a 140 IJm nylon mesh and transferred into conical tubes 
containing 10 ml of suspension buffer I containing Ca:2+ -free bicarbonate 
buffer plus CaCb 0.125mM and BSA 5mg/ml. After the myocytes were 
pelleted by centrifuging at 300rpm for -10 min, the supernatant was 
aspirated and the myocytes were resuspended in suspension buffer II 
containing Ca2+ -free bicarbonate buffer plus CaCb 0.250mM and BSA 
5rng/ml. The final cell pellet was suspended in suspension buffer III 
containing Ca2+ -free bicarbonate buffer plus CaCI2 0 . 500mM and BSA 
5mg/ml. The fresh isolated cardiomyocytes were collected by centrifuging at 
300rpm for 1 Omin.To reduce contamination, the perfusion setup was washed 
with 70% alcohol and then rinsed three times with sterillized distilled water 
before cannulation. All the solutions were filtered (0.2-lJm filter) and 
equilibrated with 95% Or5% CO2 for at least 20 min before use. 
6. Culture of adult mouse cardiac myocytes97 . 
16 
Culture dishes were precoated for 8h with 10 IJg/ml mouse laminin 
(GIBCO) in phosphate-buffered saline (PBS; GIBCO) with 1 % 
penicillin-streptomycin (PS; GIBCO) at room temperature. Freshly isolated 
cardiac myocytes were suspended in minimal essential medium (MEM; 
Si~lma M1018) containing 1.2 mM Ca?+, 2.5% preselected fetal bovine serum 
(FBS; GIBCO), and 1 % PS (pH 7.35-7.45). The myocytes were plated at 
1 >: 104 cells/cm2 in MEM containingl 2.5% FBS and 1 % PS. After 1 h of 
culture in a 5% CO2 incubator at 37°C, the medium was changed to FBS-free 
MEM and this was changed every 48 h during culture. 
7. Western Blotting 
After the cardiomyocytes wel"e cultured for 1 day, insulin was added 
to each dish at a concentration of 0,0.1, 1,3,5, 10,20,301 or 90nM for 40min. 
The cultured cardiomyocytes were collected and lysed by lysis buffer 
containing 2% SOS, 10% glycerol, and 62.5 mmollL Tris (pH 7.0) and then 
sonicated. Cell proteins were collected by centrifuging at 12 000 rpm at 4°C 
for 10 minutes. The protein concentration was determined, and the sample 
was mixed with loading buffer (40 mmol/L Tris-Hel, pH 6 .. 8, 1 % SOS, 50 
mmol/L dithiothreitol, 7.5% glycerol, 0.003% bromophenol blue) and heated 
at 95°C for 5 minutes and then subjected to electrophoresis on a SOS-PAGE 
gel at 120 V. After electrophoresis , the proteins were transfHrred to a 
nitrocellulose membrane in transfer buffer containing 20 rnmollL Tris, 152 
mrnol/L glycine, and 20% methanoL The membranes werE~ rinsed briefly in 
PBS and blocked in blocking buffer (5% milk and 0.5% BSA) at room 
temperature for 2 hours .. After blockin<g, the membranes were incubated with 
17 
antibodies against P-IR, P-AKT, P-4EBP, P-GSK-3b and actin, thEm washed 
3 times with TBS-T containing 0.05% Tween-20 and incubated with 
secondary horseradish peroxidase-conjugated antibody for 1 hour. Signal 
detection was facilitated with enhanced chemiluminescence (ECl kit, 
Amersham). Actin expression was used as a loading control. 
8. Phenylephrine administration by pump implantation 
Two-month old FVB control, Mk and Mb7 mice (three woups) were 
used. Each group of mice was treated with phenylephrine (PE) or PBS 
(vehicle control) for 28 days. Alzet miniosmotic pumps (Alza Corp., Mountain 
View, CA, USA) containing PE (50 mg/kg/day) or PBS were surgically 
inserted dorsally and subcutaneously under anesthesia by mixture of 
ketamine (50 mg/kg) and xylazine (2.5 mg/kg) given i.p. 
9. Histological Study 
The mice were anesthetized with a combination of ketamine 
(50 mg/kg) and xylazine (2.5 mg/kg, i.p.), the hearts were excised and 
immersed in formalin buffer over night, and then the hearts were embedded 
in paraffin. 5 /-lm heart sections were placed on slides, deparafflinized and 
stained with hematoxylin/eosin for histology and with picric acid for analysis 
of collagen accumulation. The solution of picric acid (saturated, 1 Q/b) contains 
O. 'I % Sirius red for staining collagen and 0.1 % Fast Green for staining 
non-collagen proteins. The sections were examined with Nikon Eclipse E600 
by light microscopy and images were acquired with SPOT camera. The 
quantitative analysis of the interstitial fibrosis were done by Adobe 
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Photoshop software. 
10. Statistical Analysis 
Data are described by mean ±SE for normally distributed variables. 
For all statistical analyses, 1-way or 2-way ANOVA model and Tukey's 
post-hoc test were performed for repeated measures. Single comparisons 




The data are divided into three parts: in vivo studies, Langendorff 
perfused heart studies and in vitro cultured cardiomyocyte studies. Figures 4, 
6 and 11 were provided by Dr. Rajakumar Donthi Figures 12 and 13 were 
provided by Qianwen Wang. The author is I~esponsible for figures 13, 9, 10, 14, 
15,16 and 17. Dr. Rajakumar Donthi and the author collaborated on the 
research shown in figures 5 and 7. 
1. In Vivo analysis 
1.1 The content of F-2,6-P2 in FVB, Mk and Mb mice is shown in 
figure 4. In Mk mice, the kinase active/bisphosphatase inactive PFK-2 
mutant cDNA was transfected into FVB background mice and was 
overexpressed specifically in hearts via a driver of (j -myosin heavy chain 
( (j -MHC) promoter. In Mb mice, the kinase inactive/bisphosphatase active 
PFK-2 mutant cDNA was transfected into FVB background mice and was 
overexpressed specifically in hearts being driven by (j -MHC promoter. FVB 
mice were used as wild type control. F-2,6-P2 increased 3 fold in Mk mice 
and decreased to 50% in Mb mice compared to FVB control mice. 
1.2 The measurement of heart to body weight ratio. In Mk and Mb 
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mice, the ratio of heart weight to body weight significantly increased 15% and 
5% respectively compared to that in FVB control mice as shown in figure 5. 
1.3 Histology analysis in FVB, Mb and Mk mice is shown in figure 6 
and figure 7. Cardiac fibrosis was significantly increased in both Mk and Mb 
transgenic hearts compared to FVB control mice. 
1.4 The effects of treatment with phenylephrine on Mk, Mb and FVB 
control mice is shown in figures 8, 9 and 10. Phenylephrine treatment 
increased cardiac afterload, inducing heart failure. At a dose of 50rng/kg/day 
of phenylephrine, Mk and Mb transgenic mice had higher mortality than FVB 
control mice. The death of cardiomyocytes by HE staining was observed in 
Mk and Mb hearts but not in FVB control hearts. Furthermore, hearts from 
Mb mice seemed weaker than Mk mice. 
2. Langendorff perfused heart data 
2.1 The effect of Mb transgene on cardiac glycolysis was assessed 
in Langendorff-perfused hearts by measuriing the consumption of 5-tritiated 
glucose and the production of lactate. 3H20 is released from the metabolism 
of [5··3H] glucose by the triose-phosphate isomerase and the enolase steps of 
the ~llycolytic pathway. As shown in figure "11, both 3H20 and lactate release 
were significantly reduced in Mb transgenic hearts. Perfusion pressure was 
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Fig.4. F-2 ,6-P2 content in Mk, Mb and FVB control mice. F-2,6-P2 increased 
significantly, almost three fold higher in Mk than in FVB control whi le F-2,6-P2 
content in Mb mice decreased significantly to 50% of FVB control. The 
values shown are mean ±SE and were analyzed by one way ANOVA (*: 
p<0 .05, n=4/each group) 
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Fig .5.The figure shows the heart to body weight ratio in FVB, Mb and Mk 
mice. The ratio of heart to body weight significantly increased 5% in Mb mice 
and 15% in Mk mice compared to FVB control. Therefore Mb and Mk hearts 
showed mild hypertrophy. The data were analyzed by one way ANOVA 
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Fig.6. Collagen accumulation in FVB and Mb hearts. Sirius red staining was 
visualized at x40 and photographed. A, representative collagen stain ing for 
FVB and Mb mice . B, scoring of collagen content in 14 photographs taken 
from FVB (3) and Mb (4) mouse hearts . Staining was rated by a blind 
observer on a sca le of 0-2, where 0 indicates mi ld, 1 increased, and 2 severe 
interstitial accumulation of co llagen. The va lues shown are mean ± S.E. and 
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Fig . 7. Histology of FVB and Mk hearts. Collagen accumulation was visualized by 
Sirius red staining at x40 . A, representative Sirius red staining of FVB and Mk 
hearts. B, scoring of collagen content in 30 photographs taken from FVB (3) and 
Mk (3) mouse hearts. Staining intensity was rated by Adobe Photoshop software . 
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Fig.8. Survival curves of Mb, Mk and FVB mice following treatment of 
phenylephrine for 28 days (implantation of pumps at dose of 50mg/kg/day). 
Higher mortalities in transgenic mice Mb and Mk were found; moreover, the 
mortality of Mb mice was higher than of Mk mice. Unfortunately, No significant 
differences were found within the comparisons of Mk vs. Mb, Mk vs . FVB and FVB 
vs . Mb through Kaplan-Meier survival analysis (Mb vs . FVB ' , p=O.067, n=8/ 
each group ). It is possible that if more mice are tested, a significant difference 




Fig.9 . HE staining on FVB control, Mb and Mk hearts after being treated with 
phenylephrine for 3 days. The HE staining was visualized at x40 and 
photographed . The death of cardiomyoctyes was found in Mb and Mk not in FVB 
control mice. The hearts from Mk and Mb mice seemed more susceptible to 
phenylephrine treatment than that from FVB control mice. 
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FIGURE 10 
PE treatment Saline control 
Fig. 1 O. Histology of FVB hearts with phenylephrine and saline treatment 
respective ly. Sirius red staining was visua lized at x40 and photographed . Fibrosis 
accumulated in the heart from FVB mice with PE treatment for 28 days compared 
to that from FVB control mice with saline treatment 
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hearts throughout the experimEmt. After addition of insulin to the perfusate, 
the difference in metabolism between transgenic and control hearts became 
even greater because of a clearly diminished response to insulin in 
transgenic hearts (Fig. 11 C and D). At the end of the 50-min perfusion with 
insulin, 5-tritiated glucose consumption was increased by 70% in FVB hearts 
but only by 34% in transgenic hearts (Fig. 11 C). Similarly, lactate output was 
increased by 90% in FVB hearts but only by 25% in Mb hearts (Fig. 11 D). 
The differences in the response to insulin were significant (p < 0.02). 
2.2 Effect of Kinase Active PFK-2 on Cardiac Glucose Metabolism 
The effect of Mk transgene on glycolysis was assessed in 
Langendroff-perfused hearts by measuring metabolism of 5-tritiated glucose 
and lactate production. Glycolysis was measured by the release of tritiated 
water through the triose phosphate isomerase reaction. As shown in 
Figure 12, in the presence or absence of palmitate, the release of 3H20 and 
lactate was significantly elevated in Mk transgenic hearts compared to 
control hearts. The Mk effect was evident both before and after addition of 
insulin. The increase in glycolysis did not appear to be related to contractility 
or perfusion pressure: no significant difference was observed for contractility 
between transgenic and control hearts at any time point (data not shown). 
Also in both groups, perfusion pressure averaged 65 mm Hg while the flow 
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Fig.11. Cardiac glycolysis and stimulatory effect of insulin were reduced in 
Mb mice. Glycolysis was measured by consumption of [5-3 H] glucose (A) and 
lactate release (8). The lower ~Iraphs show the percent increase in glycolysis 
(C) and lactate release (0) produced by the 50min stimulation with insulin. 
Values shown are mean ± S.E. for FVB (12) and Mb (14) mice. Panels A and 
B were analyzed by two-way repeated measurBS ANOVA followed by Tukey 
post-hoc test. Panels C and 0 were analyzed by Student's t test. ., p < 0.05; 
.. , p < 0.002; #, p < 0.02. 
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To determine if the transgene altered the effect of palmitate, the results for 
tritiated water release were replotted in Figure "13, As shown in Figure 13A 
palmitate significantly reduced glycolysis in FVB hearts but had no clear 
effect on glycolysis in Mk transgenic hearts (Figlure 13B), 
3. In Vitro data on insulin signaling 
Cardiomyocytes were challenged by insulin at different 
concentrations (0, 0,1, 1,0, 3,0, 5,0, 10,0, 20,0, 30.0 and 90.0 nM). Total 
proteins from the cultured cardliomyocytes were isolated by lysis buffer and 
used for Western blot analysis. The insulin signals including Phospho-AKT 
(p-AKT), Phospho-insulin receptor (P-IH), Phospho-4EBP1 and 
Phospho-GSK-3b were investi~lated, 
3,1 P-AKT and P-IR signals in FVB, Mb and Mk mice (see figure 14) 
P-AKT signals in cultured cardiomyocytes were significantly higher 
in Mk and Mb transgenic mice when challenged by different concentrations of 
insulin compared to FVB control mice, The maximum increase of P-AKT signal 
in Mk and Mb mice reached 20% at 20 nM insulin, P-AKT si~lnal of Mk mice was 
similar to that of Mb mice, EC50 for P-AKT in Mk mice was 2,AnM and maximum 
response in Mk mice was 0,24, EC50 and maximum response for P-AKT in Mb 
mice were 2,3nM and 0.252 respectively, and ECE10 and maximum response for 
P-AKT in FVB control mice were 2,5nM and 0,188 respectively, The response of 
P-IR to insulin stimulation among the three group mice was similar, 
3.2 Replot of P-IR curve vs. P-AKT curve in FV8, Mb and Mk mice 
(see figure 15) 
P-AKT signals reached peak level at 20nM of insulin stimulation in 
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all three group mice. Surprisingly the increase in P-AKT was evident at 1 nM 
while the P-IR response did not begin until 5nM insulin. 
3.3 P-4EBP1 signal in FVB, Mb and MK mice in figure 16 
P-4EBP1 is a downstream product of P-AKT. According to previous 
results, insulin concentration of 10 and 20 nM was chosen. P-4EBP1 signal was 
significantly increased in all three groups of mice with insulin treatment 
compared to non-insulin stimulated mice. No significant diffnrences were found 
among the three groups of mice with insulin treatment. 
3.4 P-GSK-3b signal in FVB, Mb and MI{ mice as shown in figure 17. 
P-GSK-3b is another downstream product of P-AKT. The insulin 
concentration of 10 and 20 nM was also chosen. P-Gi,sK-3b signal was 
significantly increased in all three groups of mice with insulin treatment 
compared to non-insulin stimulated mice. No significant differences were found 
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Fig.12. Effect of kinase active PFK-2 on glycolysis with or without 0.4 mM 
palmitate before and after addition of 200I-lU/ml insulin. I-liearts were isolated 
and glycolysis was measured using 5-3H-glucose (A) Glycolysis without 
palmitate. (B) Glycolysis with palmitate (C) LactaIe release without 
palmitate (0) Lactate release with palmitate. The valuBs for FVB and Mk 
were compared by two way ANOVA (*: p < 0.05). Values shown are means ± 
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Fig.13. The effect of palmitate on glycolysis in FVB mice (A) and Mk mice (B). 
Two way ANOVA indicated that palmitate significantly reduced glycolysis in 
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Fig .14. Log concentration-response curves for P-AKT and P-IR signals in 
cultured cardiomyocytes when stimulated by different concentrations of 
insu lin . The signals of P-AKT in A were found significantly higher in Mk and 
Mb mice compared to FVB mice. The maximum increase of P-AKT signals in 
Mk and Mb mice reached 20%. ECso of P-AKT in Mk mice was 2.4nM and 
maximum response in Mk mice was 0.24. ECso and maximum response for 
P-AKT in Mb mice were 2.3nM and 0.252 respective ly, and ECso and 
maximum response for P-AKT in FVB contro l mice were 2.5nM and 0.188 
respective ly No significance was found between Mk and Mb mice . In B, it is 
shown that the response of P-IR to insulin stimu lation was sim ilar and no 
significant differences were found among the three groups. (*, **, p<0.05 by 
2-way ANOVA analysis vs. FVB control mice) 
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FIGURE 15 
A: FVB mice B: Mb mice C: Mk mice 
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Fig .15. P-IR and P-AKT in FVB (A), Mb (B) and Mk (C) mice. P-AKT signals 
reached peak level at 20nM of insulin stimulation in all three group mice. 
Surprising ly the increase in P-AKT was evident at 1 nM while the P-IR 
response did not begin until 5nM insulin. 
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Fig,16, P·4EBP1 in cultured cardiomyocytes challenged by insulin at 0, 10 or 
20,OnM , P·4EBP1 signal was significantly increased in all three groups of 
mice with insulin treatment compared to non·insulin stimulated group, No 
significant differences were found among the three groups of mice with 
insulin treatment (* , p<0 ,05 by one way AN OVA vs, OnM insulin) 
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FIGURE 17 
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Fig.17. P-GSK-3b in the cultured cardiomyocytes challenged by insulin at 0, 
10 or 20.0nM . P-GSK-3b signal was sign ificantly increased in all the three 
groups of myocytes with insulin treatment compared to non-insulin 
stimulated myocytes. No significant differences were found among the three 
groups of mice with insulin treatment (*, p<0 .05) 
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DISCUSSION 
Our data show that the F:-2,6-P2 content in Mk hearts was increased 
3 fold compared to FVB control, in contrast F-2,6-P2 in I\/Ib hearts decreased 
to 50% of control. F-2,6-P2 is a potent stimulator of the ,glycolytic regulatory 
enzyme PFK1. The glycolytic effect of the Mk and Mb transgene was 
assessed in Langendorff-perfused hearts by the release of tritiated water 
from 5-tritiated glucose through the triose phosphate isomerase reaction, 
while lactate was also detected. As shown in figure 12, in the presence or 
absence of palmitate, the release of 3H20 and lactate was significantly 
elevated in Mk transgenic hearts compared to control hearts. Whereas in Mb 
transgenic hearts shown in figure 11, the release of 3H20 and lactate 
decreased significantly in the absence of palmitate. The Mk and Mb 
transgenic effects were evident both before and after the addition of insulin. 
As shown in Figure 13B palmitate could not significantly reduce glycolysis in 
Mk transgenic hearts but was effective in FVB hearts (Figure 13A), 
demonstrating that regulation of F-2,6-P2 could overcome fat-induced 
glycolytic inhibition. Both increased glycolysis caused by elevated F-2,6-P2 in 
Mk mice and decreased glycolysis caused by reduced 1F-2,6-P2 in Mb mice 
produced detrimental actions in heart such as hypertrophy and cardiac 
fibrosis as shown in figures 5, 6 and 7. Treatment with phenylephrine was 
39 
also used to assess heart capabilities from FVB controll, Mb and Mk mice. 
Phenylephrine usually increase cardiac afterload, as data in figure 10 shows 
that stronger perivascular collagen deposits WEire found in FVB control mice 
after being treated with phenylephrine for 28 days. Figure 8 shows higher 
mortality in Mb and Mk transgenic mice, moreover, mortality of Mb mice was 
slightly higher than that of Mk mice. When the mice were treated with 
phenylephrine for :3 days, HE staining data in figure 8 shows cardiomyocyte 
death in Mb and Mk mice but not in FVB control mice. Therefore, Both Mk 
and Mb hearts seemed weaker ttlan those of FVB control mice. 
Glucose toxicity and Lipid toxicity in Mb and Mk micE~ 
As illustrated in Fi~lure 1 and 2, there is a balance between the 
metabolism of glucose and that of fatty acid, which is called the Randle cycle. 
Increased glucose utilization may inhibit fatty acid oxidation and result in the 
accumulation of fatty acid in cytosol, while decreased glucose utilization may 
enhance the fatty acid utilization and increase cellular oxidative stress. In Mk 
transgenic mice, accumulation of fatty acid in cardiomyoctyes due to 
increased glucose utilization could result in lipotoxicity as shown in Figure 3. 
The lipotoxicity may cause cardiac dysfunction, apoptosis and insulin 
resistance through multiple signal pathways, eventually resulting in cardiac 
hypertrophy and heart failure. Increased glycolysis stimulated by F-2,6-P2 
also can cause glucotoxicity, for which two pathways can be hypothesized, 
one is by PKC, another is by AGE55 . In Mb mice, decreased glycolysis will be 
expected to increase fatty acid oxidation, and increased consumption of fatty 
acids may provoke more ROS from mitochondria. Decreased glycolysis also 
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can cause glucose toxicity through other pathways, one is to increase polyol 
pathway influx, another is hexosamine pathwal5. 
In Mb mice, reduced F-2,6-P2 will be expectHd to decrease the 
activity of PFK-1, the upstream ml3tabolites of glycolysis at the point of PFK-1 
may accumulate due to the reduced activity of PFK-1 such as F-6-P and/or 
G-6-P and glucose in cardiomyocytes. Accumulation of glucose in 
cardiomyocytes could activate the polyol pathway and the accumulated 
F-6-P could stimulate the hexosamine pathway. In the polyol pathway, aldose 
reductase is the first enzyme and catalyses the NADPH-dependent reduction 
of a wide variety of carbonyl compounds such as glucose to sorbitol, with 
consumption of NADPH, anel further the sorbitol can be oxidized to fructose 
by the enzyme sorbitol dehydrogenase, with NAD+ reduced to NADH 55. In 
this polyol pathway, NADPH is decreased and more glutathione (GSH) 
needs to be generated, but too much consumption of GSH can increase 
intracellular oxidative stress. The reduction of glucose utilization in Mb mice 
leading to elevation of fatty acid utilization may also raise intracellular 
oxidative stress. Therefore, oxidative stress (ROS) should be very high in Mb 
mice. The increased intracHllular oxidative stress could activate multiple 
signal pathways and could result in cell apoptosis and necrosis, leading to 
cardiac dysfunction, hypertrophy and heart failure6C1 , 86. In the hexosamine 
pathway, the accumulated F-,6-P in Mb mice can be diverted from glycolysis 
and be a substrate for glutamine:fructose-6-phosphate amino transferase 
(GFAT) for producing glucosamine, and further forming UDP-N-acetyl 
glucosamine (GlcNAc).The 'GlcNAc can modify various cytosolic proteins 
and transcriptional factors by O-GlcNAcylation, either reducing or enhancing 
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their activities, which are associated with development of diabetic 
complications65 . BE!CaUSe phosphorylation plays an important role in protein 
activity and transcriptional activity, O-GlcNAcylation and phosphorylation 
often occur reciprocally in transcription factors, thus O-GlcNAcylation 
competing with phosphorylation may enhance or inhibit the transcriptional 
activities, for example, Sp1 has shown some competing sites between 
phosphorylation and O-C~lcNAcylation affecting Sp1 transcriptional 
activities65 ,96; A fourfold incrt3ase in O-acetylglucosaminylation of Sp1 result 
in a reciprocal 30% decrease in the level of serine-threonine 
phosphorylation of Sp 166 ; hyper~"ycemia can induce a .2.4-fold increase in 
hexosamine pathway activity in aortic endothelial cells, resulting in a 1.7 -fold 
increase in Sp1 O-linked GIGNAc and a 70-80% decrease in Sp1 O-linked 
phosphothreonine and phosphoserine55, 61, furthermore, hyperglycemia can 
increase expression of an 8~;-base-pair truncated PAI-1 promoter-Iuciferase 
reporter DNA containing two Sp1 sites by 3.8 fold but fails to act when the 
two Sp1 sites are mutated b5, 61. Therefore, activation of the hexosamine 
pathway by hyperglycemia may result in many changes in both gene 
expression and protein function, which together contribute to the 
pathogenesis of diabetic cornplications65 . In Mb mice, Sp1 activity may be 
increased by the hexosamine pathway due to modification of Sp1 by 
glycosylation. Sp1 activity is associated with gene expression of MMP, TIMP 
and TGF-beta, PAI,-1, which are involved in cardiac remodeling and fibrosis 
formation88 . 
In Mk transgene mice, increased F-.2,6-P2 will increase the activity 
of PFK1, producing over amount of product F-1,6-F)2. The over amount of 
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F-1,6-P2 may exceed the capacities of downstream enzymes to metabolize 
them, meanwhile F-1,6-P2 can balance reversibly with DHAP and GAP. 
Therefore increased F-2,6-P2 probably lead to thE~ accumulation of 
dihydroxyacetone phosphatf3 (DIHAP) and GAP metabolites. Accumulated 
GAP metabolites can form methylglyoxal, producing advanced glycolyation 
endproducts (AGE). AGE formed from glucose is much sllower than that from 
glucose-derived dicarbonyl precursors such as glyoxal, 3-deoxyglcosone 
and methyglyoxal84 . In Mk mice, due to high activity of PFK-1, intracellular 
methygloxal product could be hi!Jher than that in normal mice. The higher 
methygloxal content inside cells, the more intracellular AGEs produced. 
Intracellular AGE precursors can damage target cells by modifying 
intracellular proteins, by altering intracellular protein function and activities, 
and by modifying extracelluar matrix components interacting abnormally with 
other matrix component and with receptors on cells suclh as intergrins, and 
by modifying plasma proteins binding to AGE receptors, which activates 
transcription factor NF-~: B, causing pathological changes in gene 
expression 55 . DHAP accumulation will stimulate synthesis of (j-glycerol-P 
with consuming NADH. The (J -glycerol-P reacting with fatty acid-CoA forms 
phosphatidate. The phosphatidate can further be dHphosphorylated to 
produce DAG. DAG can activate the conventional PKC isoforms (01, ~, y) with 
calcium and activate novel PKC ilsoforms (0, £, 1"], 8 ) without calcium72 , 73. 
PKC isoforms ( Cl, ~, y). are up-regulated from the stage of cardiac 
hypertrophy extending to congestive heart failure, but PKC isoform ( £) is 
up-regulated especially in cardiac hypertrophy and declines in congestive 
heart failure72 . Hyperglycemia may activate PKC isoforms indirectly through 
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both ligation of AGE receptors and the polyol pathway51. In addition, PKC 
pathway also can be activated by autocrine/paracrine factors such as 
TGF-beta, ET-1 and Ang " etc. 73 . 
Activated PKCs have multiple adverse effects in diabetes, such as 
cardiac hypertroph/3. 91. For example, transgenic micE! with an increased 
number of L-type calcium channels and PKCa activation develop cardiac 
hypertrophy and severe cardiac dysfunction82; cardiac specific 
overexpression of PKCJ32 isoforrn can cause cardiac hypertrophy, fibrosis 
and contractile dysfunction. The mechanism by which PKCJ32 damages 
contractile function of heart is that PKCJ32 decreases cardiomyocyte calcium 
sensitivity by phosphorylating troponin 195. Activation of the PKCE isoform 
may lead to compensated ventricular hypertrophyB2 92. Elevated PKCo can 
trigger cardiomyocyte apoptosis and necrosis by reducing ATP !generation 
through inhibition of PDH, increasing ROS generation and increasing 
cytochrome C release56. 
Therefore, in Mb and Mk mice, the PKC pathway could bB activated 
by ROS, hexosamine pathway, DAG and AGEs respectively or together. 
The activated PKC pathway could result in necrosis and apoptosis of 
cardiomyocytes, with results of cardiac dysfunction, hypertrophy and fibrosis. 
Cardiac remodeling in Mb and Mk mice 
In the heart, cardiac myocytes occupy 90% of the myocardial mass, 
whereas 90-95<Yo of non cardiomyocytes are cardiac fibroblasts94. 
Cardiomyoctyes and non cardiomyoctyes are scaffolded by a network of 
fibrillar collagen. Based on morphology, the network can be subdivided into 
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three components: epimysium, perimysium and endomysium. The 
epimysium surrounds the surfaces of the endocardial and the epicardial 
myocardium, providing the support for endothelial and mesothelial cells. The 
perimysium circles groups of muscle fibers and the endomysium, extended 
from perimysium, surrounds individual fibers87. Fibrosis tissues can be 
divided into three groups: perivascular fibrosis, interstitial fibrosis and 
microscopic scarring69. Collagen is a stable protein whose synthesis and 
degradation is normally slow (estimated to be 80-120 days) and is regulated 
by cardiac fibroblasts 132 . 
Under pathological conditions both the synthesis and degradation 
of collagens are altered, and the accumulation of collagen results in fibrosis. 
In morphologic terms, fibrosis can be classified as reactive fibrosis e.g., an 
adverse accumulation of perimysial collagen, or as reparative fibrosis, which 
fill in the empty space due to the death of cardiomyocytes for maintaining the 
structural integrity of myocardium53 69,85. Depending upon its location and 
magnitude, collagen fiber crosslinking, and relative abundance of type I and 
III collagens, fibroSIS can adversely increase myocardial stiffness, leading to 
diastolic heart failure (DHF)85. In patients with hypertension, Extracellular 
matrix (ECM) accumulation is associated with left ventricular hypertrophy 
(LVH) and diastolic dysfunction and increases in ECM degradation seem to 
precede the transition to systolic failure85. In animal models of hypertensive 
heart disease (HHD), an increase in interstitial collagen (accumulated 
perimysium) is associated with diastolic heart failure, whereas degradation of 
endomysial and perimysial components of the collagen scaffolding is 
accompanied by ventricular dilatation and systolic hE~art failure54 Both 
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intracellular and extracellular factors are involved in the remodeling process 
(collagen synthesis and degradation). One component in this remodeling 
process is a family of proteins called extracellular matrix cjegradin~1 enzymes, 
the matrix metalloproteinases (MMPs), another is a family of proteins called 
tissue inhibitors of metalloproteinases (TIMPs). MMPs can degrade ECM 
proteins with differing degrees of specificity, the collagenases (MMP1, MMP8, 
and MMP13) initiate the ECM degradation process by cleaving the a-chains 
of type I and type II collagens and the gelatinases (MMP2 and MMP9) further 
process the collagen fragments88 . The actual activity of MMPs depends 
critically on the balance between active enzyme and TIMPs. TIMPs are 
multifunctional proteins that can inhibit the catalytic activity of MMPs, thus 
maintaining ECM homeostasis, for an example, TIMP-1 is a glycosylated 
protein and is secreted in a soluble form, forming 1: 1 complex with MMP-9 74, 
78. A disordered balance of MMP and TIMP activity in HHD can exert 
profound effects on cardiac function. For an example, the expression of 
MMP-1 and TIMP-1 in cardiomyocytes is not found in normotensive subjects 
but observed in heart failure hypertensive patients, furthermore, patients with 
diastolic heart failure (OHF) exhibit low grades of MMP-1 expression and 
patients with systolic heart failure (SHF) patients exhibit high grades of 
MMP-1 expression. No differences in cardiomyocyte TIMP-1 expression 
were observed between the two groups of patients. The expression of 
MMP-1 and TIMP-1 in interstitial matrix is found among the three groups of 
people: normal, OHF and SHF. However, the number of patients with high 
grades of interstitial MMP-1 expression in SHF group are more than that in 
OHF group. In contrast, the number of patients with high !Jrades of Interstitial 
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TIMP-1 expression in DHF are more than that in SHF group 75. lin addition, 
MMP activation can contribute to the fibrotic process by participating in a 
vicious circle in which ECM degradation promotes ECM protein synthesis 
and fibrosis. This pathway is particularly detrimental because MMP can 
degrade the native ECM very easily and the newly synthesized ECM which 
usually are oxidized and highly cross linked collagen are diffilcult to be 
degraded, favoring the accumulation of a much stiffer collagen 53. 
Myofibroblasts, converted from fibroblasts, are responsible for the 
synthesis of collagen and regulate collagen degradation through modifying 
the balance of MMPs and their inhibitors (TIMPs). Myofibroblasts are defined 
by their dual functions: fibroblast-like in terms of ECM synthesis and smooth 
muscle myocyte-like in terms of migration. Myofibroblast formation is 
controlled by growth factors, cytokines, and mechanical stimuli. Key 
hormones and cytokines for this transition are ANG II, ET-·1, and T(3F-beta 53, 
79. Myofibroblast-mediated collagen turnover is regulated by autocrine and 
paracrine factors generated within the myocardium and by endocrine 
hormones derived from the circulation such as ET-1, Ang II, TGF-beta and 
PAI_1 85 , 87. 94. Taken together, these factors, which can be synthE!sized and 
secreted by cardiomyocytes58, 6:3, 83, 89, 90, stimulate cardiac fibroblast 
conversion to myofibroblast and regulate myofibroblast mediated collagen 
turnover through modifying the balance of MMPs and TIMPs. 
In cardiac specific lipoprotein lipase knock-out mice (hLPLO), fatty 
acid utilization decreases and glucoses oxidation increase. The decreased 
fatty acid utilization results in cardiac dysfunction such as diminishBd ejection 
fraction and extensive fibrosis although glucose oxidation is increased, 
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furthermore, expression of some genes associated with cardiac fibrosis and 
matrix remodeling is increased such as TGF-beta, connective tissue growth 
factor, TIMP-1, MMP-2 and pro-collagen 1 52.The decreased fatty acid 
utilization and increased glucose oxidation are similar to that in Mk mice, 
presumably Mk mice with hypertrophy and enhanced fibrosis should 
accompany with same gene expression pattern as hLPLO mice in which 
TGF-beta, connective tissue growth factor, TIMP-1, MMP-2 and pro-collagen 
1 expression are upregulated. 
In Mb mice, the hexosamine pathway modification of the Sp1 
transcription factor by O-GlcNAcylation may increase the synthesis and 
secretion of PAI-1 and TGF-beta, and high oxidative stress (ROS) could 
activate NF-KB and AP-1 transcriptional factors. In Mk mice, elevated 
glycolysis may increase ET-1 synthesis and secretion from cardiomyocytes, 
and AGEs and DAG activate PKC pathway. PKC pathway activation would 
turn on very complicated signal networks, such as increase of expression of 
PAI-1, TGF-beta, NF-KB and AP-1 etc. These transcription factors mentioned 
above could differentially regulate MMPs and TIMPs expression by binding 
to the genes' promoter region, e.g. Sp'l for TIMP-1, TIMP-2, TIMP-3,TIMP-4 
and MMP-2, MMP-9 and MT1-MMP; Ap-1 for MMPs, TIMP-1 and TIMP-2; 
Ets for MMPs and TIMP-4; SMAD from TGF-beta for MMP-1, MMP-7, 
MMP-13 and MT1-MMP; NF-KB for MMPS59,88. 
Plasminogen activator inhibitor-1 (PAI-1) is the major inhibitor of 
tissue and urokinase plasminogen activators and thereby reduces the 
conversion of plasminogen to plasmin, an extracellular protease that 
mediates fibrinolysis and activates matrix metalloproteinases 58. RE~duction of 
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plasmin in tissues will decrease the activation of MMPs, favorin9 collagen 
accumulation. An elevated level of PAI-1 occurring in diabetes, insulin 
resistance, obesity, and hypertension has been ascribed to be a risk factor 
for development of cardiovascular disease64 . 70. 76. 80. In Mb mice, possible 
increased PAI-1 sElcretion could inhibit plasmin formation and reduce the 
activities of MMPs .. In addition, increased Sp1 activity may alsCi raise the 
expression of TIMP-1, TIMP-2, TIMP-3, TIMP-4, MMP-2, MMP-9 and 
MT1-MMP, disrupting the normal balance of MMPs and TIMPs. Therefore, 
O-GlcNAc Sp1 may be regarded as a very important factor involved in the 
pathogenesis of Mb transgenic hearts. 
Endothelin (ET)-1, a potEmt vasoconstrictor peptide from vascular 
endothelial cells, is also synthesized and secreted by cardiomyocytes and 
induces hypertrophy of cardiomyocytes 68,77. The pattern of gene expression 
of ET-1 reflects the level of the glycolytic system in cardiCimyocytes. 
Enhanced glycolysis will upregulatl3 the cardiac gene expression of ET_1 59 , 71. 
In Mk mice, high glycolysis may upregulate ET-1 expression. The 
upregulated ET-1 may increase the expression of TIMP4 and MMPs, 
affecting the balance of TIMPs with MMPs. 
TGF-beta expression is increased in the patients with left ventricular 
hypertrophy and dilated cardiomyopathy. Overexpression of TGF-beta 
transgenic mice demonstrates that TGF-beta can induce cardiac 
hypertrophl9, 90. The mechanism by which TGF-beta causes cardiac 
dysfunction is that TGF-beta stimulates fibroblast proliferation and 
conversion to myofibroblasts, and that TGF-beta induces the production of 
ECM components through cardiac myofibroblasts and fibroblasts, and that 
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TGF-beta can recruit smooth muscle cells, monocytes and fibroblasts and 
stimulate wound repair and ECM deposition 93. The nuclear factor SMAD 
from TGF-beta stimulation can bind the promoter region of MMP-1, MMP-7, 
MMP-13 and MT1-MP genes88 . Therefore in Mb and Mk mice, TGF-beta may 
be responsible for cardiac hypertrophy and fibrosis, probably through 
regulating the gene expression of IV1MP-1, MMP-7, MMP-13 and MT1-MP. 
In addition, increased intracellular oxidative stress in Mb mice and 
PKC activation in Mk mice may a1fect the expression of several MMPs and 
TIMPs, leading to unbalance of collagen synthesis and degradation59 . 
F-2,6-P2 involved in pathology of Mk and Mb mice 
When cardiomyocytes were challenged by insulin in vitro, the signal 
of P-AKT produced in Mk and Mb cardiomyocytes was significantly higher than 
that of FVB control as shown in figure14, whereas the signals of P-4EBP1, 
P-GSK-3b and P-IR were similar among cardiomyocytes from Mk, Mb and 
FVB control mice. Our data suggest that F-2,6-P2 is involved in insulin signal 
pathway below P-IR and beyond P-AKT. Possibly some middle mediator 
between P-IR and P-AKT such as IRS-1/2 or PI3K. may be affected by 
F-2,6-P:z directly or indirectly. ThEl elevated P-AKT might be associated with 
cardiac hypertrophy and matrix remodeling because P-AKT can increase 
MMP-2 gene expression81 . Cross talk between Ang II and the insulin signal 
pathways occurs on the mediator IRS1/2. Both Insulin and Ang II stimulate the 
tyrosine phosphorylation of insulin receptor substrates (IRS). IRS proteins act 
as docking proteins for phosphatidylinositol 3-kinase (PI3-kinase) and growth 
factor receptor-binding protein 2 (Grb-2), followed by signaling P-AKT from 
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Pl3-kinase or MAPKs from Grb-ii7 . F-2,6-P2 could intensify the insulin signal 
by elevating P-AKT. Possibly F-2,6-P2 can also intensify the Ang II signals, 
which are associated with cardiac hypertrophy. 
F-2,6-P2 not only regulates glucose metabolisms by allosteric effects 
on PFK-1 but also regulates expression of key enzymes and transcriptional 
factors. For example, when levels of F-2,6-P2 are elevated in the liver, 
glucose kinase (GK) expression is increased, whereas 
glucose-6-phosphotase (G6PasE~), acetyl-CoA carboxylase( ACC) and fatty 
acid synthase ( FAS) expression are reduced47. Also affected as the 
expression of some transcriptional factors are, such as reduction of ChREBP, 
PPAR alpha, PGC-1 beta and SREBP 4',. ET-1 has been shown to 
significantly enlarge cardiomyocytes and PPARa activator linhibits 
ET-1-induced increases in cardiomyocyte size67 . In Mk mice, high glycolysis 
may increase ET-1 secretion while high level of F-2,6-P2 may decrease the 
expression of PPAR-a. Therefore, high level of F-2,6-P2 combined with 
increased secretion of ET-1 could be responsible for Mk cardiac hypertrophy. 
In summary, it is probable that multiple pathways are involved in the 
observed hypertrophy and fibrosis of Mk and Mb mouse hearts. 
Transcriptional factors such as Sp'l, Ap1, SMAD and autocrine/paracrine 
factors such as PAI-1, ET-1 and TGF-beta may be upregulated and/or 
activated, regulating the balance of MMPs with TIMPs and affecting collagen 
synthesis and degradation in Mk and Mb mice hearts. F-2,6-P2 may be 
involved in the development of cardiac hypertrophy through Ang II signal 
pathway or decreasing the expression of PPARa gene directly or indimctly. 
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APPENDIX 
ACC. acetyl-CoA carboxylase 
ACS, acyl-CoA synthase 
AGE, advanced glycollyation endproducts 
AKT, protein kinase B 
ANOVA, analyses of variance 
AP-1, activating protein 1 
aPK, atypical protein kinase 
CAPP, ceramide-activated protein phosphatase 
CAPK, ceramide-activated protein kinase 
CD36, fatty acid translocase 
ChREBP, carbohydrate response element -binding protein 
CPT I, palm Itoyltransferase 
DAG, diacylglycerol 
db/db mice, leptin receptor deficient mice 
DHAP, dihydroxyacetone phosphate 
DHF, diastolic heart failure 
[eM, extracellular matrix 
ET-1, endothelin -1, 




FA, fatty acid 
FAS, fatty acid synthetase, 
FABPpm, fatty acid binding protein plasma membrane 
FAT, fatty acid transporter 
FATP, fatty acid transport protein 
FFA, free fatty acids 
G3P, glyceraldehyde<~-Phosphate 
C,6P, glucose -6- phosphate 
G-6-P, glucose-6-phosphate 
G6Pase, glucose-6-phosphotase 
GAP, D-glyceraldehyde 3-phosphate 
GAPDH, glyceraldehyde phosphate dehydrogenase 
(,FAT, glutamine:fructose-6-phosphate amino transferase 
GK, glucose Kinase 
GlcNAc, UDP-N-acetyl glucosamine 
Glut1, glucose transporter 1 
Glut4., glucose transporte 4 
Grb-2, growth factor receptor-binding protein 2 
C;SH, glutathione 
HE staining, hematoxylin-eosin staining 
HHD, hypertensive heart disease 
HK, hexokinase, 
hLPLO, lipoprotein lipase knock-out mice 
IKB, inhibitor of NF-KB 
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IRS, insulin receptor substrate 
LPL, lipoprotein lipase 
LVH, left ventricular hypertrophy 
MAPKs, mitogen-activated protein kinases 
MCO, malonyl-CoA decarboxylase 
a-MHC, a-myosin heavy chain 
~-MHC, ~-myosin heavy chain, , 
MMPs, matrix metalloproteinases 
NAOPH, nicotinamidl~ adenine dinucleotide phosphate 
NF-kB, nuclear factor-kappa B 
PAI-1, plasminogen activator inhibitor-1 
PARP, poly (AOP-ribose) polymerase 
PBS, phosphate-buffered saline 
POC , pyruvate decarboxylase 
POH, pyruvate dehydrogenase 
PE, phenylephrine 
PFK-1, phosphofructose kinase-1 
PFK-2, phosphofructose kinase-2 
PGC-1 beta, peroxisome proliferator-activated receptor ~lamma coactivator 1 
beta 
P-4EBP1, phosphorylation of eukaryotic translation initiation factor 4E binding 
protein 1 
P-AKT, phospho-AKT 
P-GSK-3b, phosphorylation of glycogen synthase kinase 3 beta 
PIP3, phosphatidylinositol (3,4,5) trisphosphate 
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PI3K, phosphatidylinositol 3-kinase 
P-IR, phospho insulin receptor 
PKC, protein kinase C 
PPAR-a, peroxisome proliferator-activated receptor-a 
PS, penicillin-streptomycin 
PTEN, phosphatase and tensin homologue deleted on chromosome 10 
ROS, reactive oxygen species 
SREBP, sterol-regulatory element-binding protein 
SHF. systolic heart failure 
Sp1, sequence-specific transcription factor 1 
SMAD, mothers against decapentaplegic homolog 
TCA cycle, citric acid cycle (Krebs cycle) 
Tg, triglycerides 
TGF-beta, transforming growth factor beta 
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